Exabis Library
Welcome to the e-CCO Library!
P330 Inflammatory Bowel Disease (IBD) patients frequently report adverse drug reactions during biologic therapy: A multicentre, prospective, patient-reported pharmacovigilance monitoring system
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P330: A national survey on therapeutic education in inflammatory bowel disease by an association of caregivers and expert patients: French Association for Therapeutic Education in inflammatory bowel disease (AFEMI)
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P330: A prospective trial to evaluate the feasibility of a mobile app in patients with inflammatory bowel disease under maintenance therapy
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P330: Discontinuation of corticosteroids among ulcerative colitis patients treated with vedolizumab in the United States
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P330: Immunity in patients with inflammatory bowel disease on biologic therapy after COVID 19 vaccination
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P330: Long-term outcomes following a switch from originator adalimumab to the biosimilar SB5 (Imraldi) in IBD
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P330: Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P330: Vitamin D insufficiency in patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P331 Productivity loss in patients with inflammatory bowel disease receiving treatment for iron deficiency anaemia: A comparison of ferric maltol and IV iron
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
Wednesday, 3 March 2021, 4:12 PM by Dauren Ramankulov
P331: Allopurinol and azathioprine co-therapy or thioguanine dose splitting: shifting the shunters in the mercaptopurine pathway in a paediatric inflammatory bowel disease population—a single-centre experience
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P331: Composite outcomes in Crohn’s disease: a systematic review and meta-analysis of observational studies
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P331: Development of a novel transabdominal ultrasound disease activity score in patients with ulcerative colitis (UCUS score)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P331: Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P331: Real-world assessment of biological treatment of inflammatory bowel disease at an Austrian Referral Centre: the ULTIMATE study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P331: Risk Factors and Prediction Model for Fecal Incontinence in Patients with Crohn's Disease: A Multicenter Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P331: The safety of tioguanine exposure during pregnancy: a case series of seventy-three pregnancies
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P332 Mindfulness-based stress reduction and cognitive intervention improve the health-related quality-of-life and ability to work in Crohn’s disease patients: A randomised controlled trial
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P332: A treat-to target strategy guided by pan-enteric valuation in paediatric Crohn’s disease improves outcomes at 2 years
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P332: External validation of intestinal ultrasound scores to detect endoscopic activity in children and adults with Crohn's disease: A prospective cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P332: Group-based Acceptance and Commitment Therapy (ACT) is acceptable and effective at reducing psychological distress in patients with Inflammatory Bowel Disease (IBD).
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM